Table 6

Expression of soluble markers in oesophageal tissues

	Visit	Mean	SD	Change from screen (%)	p Value
Eotaxin-1⁺ cells per hpf
Mepolizumab (n = 5)	Screening	84.12	31.76
	Week 4	24.95	10.15	−70	0.0001
	Week 13	20.89	13.91	−75	0.0002
Placebo (n = 6)	Screening	49.47	21.47
	Week 4	42.83	27.27	−13	NS
	Week 13	41.53	26.78	−16	NS
Eotaxin-2⁺ cells per hpf
Mepolizumab (n = 5)	Screening	90.84	38.41
	Week 4	19.27	10.66	−79	0.0001
	Week 13	23.45	20.65	−74	0.0005
Placebo (n = 6)	Screening	58.99	29.41
	Week 4	47.13	28.15	−20	NS
	Week 13	52.14	30.08	−12	NS
Eotaxin-3⁺ eosinophils per hpf
Mepolizumab (n = 5)	Screening	62.63	38.48
	Week 4	14.63	6.31	−77	0.0007
	Week 13	19.72	22.23	−69	0.0041
Placebo (n = 6)	Screening	45.01	35.39
	Week 4	36.14	21.94	−19	NS
	Week 13	39.19	32.63	−13	NS
Eotaxin-3 expression by epithelial cells (score)
Mepolizumab (n = 5)	Screening	1.2	1.4
	Week 4	1.5	1.7	+25	NS
	Week 13	1.2	1.4	0	NS
Placebo (n = 6)	Screening	1.5	1.4
	Week 4	2.0	1.5	+33	NS
	Week 13	1.75	1.5	+17	NS
IL-5⁺ cells per hpf
Mepolizumab (n = 5)	Screening	72.17	43.79
	Week 4	28.87	18.53	−60	0.006
	Week 13	29.91	27.31	−59	0.004
Placebo (n = 6)	Screening	53.93	33.81
	Week 4	49.53	19.72	−8	NS
	Week 13	48.61	27.29	−10	NS
TNFα expression by epithelial cells (score)
Mepolizumab (n = 5)	Screening	2.4	0.5
	Week 4	2.3	0.5	−4	NS
	Week 13	2.3	0.5	−4	NS
Placebo (n = 6)	Screening	2.5	0.6
	Week 4	2.25	0.6	−10	NS
	Week 13	2.1	0.7	−16	NS
EDN expression by eosinophils (score)
Mepolizumab (n = 5)	Screening	1.80	0.45
	Week 4	1.25	0.44	−31	0.0001
	Week 13	1.26	0.45	−30	0.0001
Placebo (n = 6)	Screening	1.66	0.38
	Week 4	1.24	0.62	−25	0.006
	Week 13	1.64	0.66	−1	NS
Extracellular EDN deposition (score)
Mepolizumab (n = 5)	Screening	2.11	0.44
	Week 4	1.74	0.68	−18	0.0073
	Week 13	1.65	0.17	−22	0.0007
Placebo (n = 6)	Screening	2.06	0.48
	Week 4	1.81	0.61	−12	NS
	Week 13	2.01	0.46	−2	NS

EDN, eosinophil-derived neurotoxin; hpf, high power field; IL-5, interleukin-5; NS, non-significant; TNFα, tumour necrosis factor α.